You are on Trendlyne United States. Click here to go to India website or make United States as your default
  1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : MAJOR PHARMACEUTICALS
  4. PTC THERAPEUTICS INC

PTC Therapeutics Inc XNAS: PTCT

PTC Therapeutics Inc Live Share Price Today, Share Analysis and Chart

Download real time

48.19 0.80 (1.69%)

100.79% Gain from 52W Low

1.1M XNAS Volume

XNAS 21 Apr, 2025 5:30 PM (EDT)

Watchlist

Portfolio

Share
Board Meeting
The next board meeting for PTC Therapeutics Inc is on 25 Apr 2025 for the purpose of PTC Therapeutics Inc First Quarter Earnings Conference Call for 2025 See details

PTC Therapeutics Inc Key Metrics

Default

Market Capitalization

High in industry
3,800.7

PE TTM

Negative PE TTM
-10.5

PEG TTM

Negative PEG TTM
-0.2

Price to Book

Negative Price to Book
-3.5

Institutional holding current Qtr %

High in industry
103.3

Revenue Growth Qtr YoY %

Negative Revenue Growth Qtr YoY %
-30.6

Operating Revenue growth TTM %

Negative Operating Revenue growth TTM %
-14

Net Profit Qtr Growth YoY %

Below industry Median
57.7

Net Profit TTM Growth %

Below industry Median
42

Operating Profit Margin Qtr %

Negative Operating Profit Margin Qtr %
-7.4

Operating Profit Margin TTM %

Negative Operating Profit Margin TTM %
-18.2

Piotroski Score

Below industry Median
2

Rel Perf vs Sector quarter%

10.5

RoA Annual %

Negative RoA Annual %
-20.2
All financials are in USD Million and price data in USD
VIEW MORE

16

S

4

W

2

O

1

T

SWOT Analysis

Check P/E Buy Sell Zone

This stock has negative PE


PTC Therapeutics Inc Live Price Chart

Switch to TradingView
Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Created with Highcharts 7.2.2Dec '22Dec '23Dec '24Dec '25Dec '26500100015002000Actual RevenueAvg. Estimate
Miss

PTC Therapeutics Inc's Revenue was lower than average estimate 3 times in past 3 years

EPS forecast

Current EPS
-4.7
Avg. Estimate
-1.2
Low Estimate
-6.9
High Estimate
10.3
Current EPS
Avg. Estimate
Hit

EPS is expected to grow by 75.3% in FY25

Consensus Recommendation

15 ANALYST Recommendations
BUY

Created with Highcharts 7.2.21Strong Sell1Sell4Hold3Buy6Strong Buy

The consensus recommendation from 15 analysts for PTC Therapeutics Inc is BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get

PTC Therapeutics Inc Stock Analysis

PTC Therapeutics Inc stock analysis with key metrics, changes, and trends.

PTC Therapeutics Inc MetricVALUECHANGE %TRENDANALYSIS
Annual Revenue$806.78 M13.97%negative

Annual Revenue fell 13.97%, in the last year to $806.78 M. Its sector's average revenue growth for the last fiscal year was 7.49%.

Annual Net Profit$363.3 M42.02%positive

Annual Net Profit rose 42.02% in the last year to $363.3 M. Its sector's average net profit growth for the last fiscal year was -32.44%.

Price to Earning Ratio-10.46-negative

Price to Earning Ratio is -10.46, which is negative.

Stock Price$48.1990.32%positive

Stock Price rose 90.32% and outperformed its sector by 83.51% in the past year.

Quarterly Revenue$213.17 M30.58%negative

Quarterly Revenue fell 30.58% YoY to $213.17 M. Its sector's average revenue growth YoY for the quarter was 5.79%.

Quarterly Net profit$65.89 M57.71%positive

Quarterly Net profit rose 57.71% YoY to $65.89 M. Its sector's average net profit growth YoY for the quarter was -41.98%.

Mutual Fund Holding53.42 %0.1%positive

Mutual Fund Holding increased by 0.1% in the last quarter to 53.42.

Promoter Share Holding1.54 %0.25%positive

Promoter Share Holding increased by 0.25% in the most recent quarter to 1.54%.

Interest Coverage Ratio-1.17-negative

Interest Coverage Ratio is -1.17, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

Institutional Holding103.29 %-0.06%negative

Institutional Holding decreased by 0.06% in the last quarter to 103.29.

VIEW LESS


Loading data..

PTC Therapeutics Inc - Company Profile

What does PTC Therapeutics Inc do?

PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.

PTC Therapeutics Inc Management structure

All Gross Remunerations are in USD
Ms. Christine Utter
Senior Vice President, Chief Accounting Officer and Head, People Services
-
2024
Gross Remuneration
Year
Dr. Matthew B. Klein, F.A.C.S.,M.D.,M.S.
Director, President and Chief Executive Officer
-
2024
Gross Remuneration
Year
Mr. Pierre Gravier
Chief Financial Officer
-
2024
Gross Remuneration
Year

PTC Therapeutics Inc Board of directors

All Gross Remunerations are in USD
Dr. Glenn D. Steele, M.D., Ph.D.
Independent Director
-
2024
Gross Remuneration
Year
Mr. David P. Southwell
Independent Director
-
2024
Gross Remuneration
Year
Dr. Jerome Bernard Zeldis, M.D.,PhD
Independent Director
-
2024
Gross Remuneration
Year
Mr. Michael Schmertzler
Chairman of the Board
-
2024
Gross Remuneration
Year
Dr. Allan Jacobson, PhD
Independent Director
-
2024
Gross Remuneration
Year
Ms. Emma Reeve
Independent Director
-
2024
Gross Remuneration
Year

PTC Therapeutics Inc FAQ

How is PTC Therapeutics Inc today?
PTC Therapeutics Inc today is trading in the green, and is up by 1.69% at 48.19.
PTC Therapeutics Inc is currently trading up 1.69% on an intraday basis. In the past week the stock rose 12.12%. stock has been up 9.92% in the past quarter and rose 90.32% in the past year. You can view this in the overview section.